MA37799A1 - Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci - Google Patents

Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Info

Publication number
MA37799A1
MA37799A1 MA37799A MA37799A MA37799A1 MA 37799 A1 MA37799 A1 MA 37799A1 MA 37799 A MA37799 A MA 37799A MA 37799 A MA37799 A MA 37799A MA 37799 A1 MA37799 A1 MA 37799A1
Authority
MA
Morocco
Prior art keywords
women
dhea
vagina
symptoms
atrophy
Prior art date
Application number
MA37799A
Other languages
Arabic (ar)
English (en)
Other versions
MA37799B2 (fr
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49996456&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37799(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of MA37799A1 publication Critical patent/MA37799A1/fr
Publication of MA37799B2 publication Critical patent/MA37799B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une dha intra vaginale utilisée pour le traitement d'au moins un état choisi dans le groupe constitué par un trouble hypoactif du désir sexuel féminin, un trouble de l'excitation sexuelle féminine, un trouble de l'orgasme féminin et un trouble de stimulation de l'intérêt sexuel féminin chez une femme qui (1) ne souffre pas de symptômes d'atrophie vulvo-vaginale et/ou (2) ne souffre pas de dyspareunie de modérée à aiguë.
MA37799A 2012-07-25 2013-07-18 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci MA37799B2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675717P 2012-07-25 2012-07-25
US13/942,977 US20140045806A1 (en) 2012-07-25 2013-07-16 Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
PCT/CA2013/000654 WO2014015416A1 (fr) 2012-07-25 2013-07-19 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Publications (2)

Publication Number Publication Date
MA37799A1 true MA37799A1 (fr) 2016-08-31
MA37799B2 MA37799B2 (fr) 2021-02-26

Family

ID=49996456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37799A MA37799B2 (fr) 2012-07-25 2013-07-18 Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci

Country Status (25)

Country Link
US (1) US20140045806A1 (fr)
EP (1) EP2877183B1 (fr)
JP (3) JP2015522625A (fr)
KR (4) KR102258122B1 (fr)
CN (2) CN111529536A (fr)
AR (1) AR091907A1 (fr)
BR (1) BR112015001479A2 (fr)
CA (2) CA2972491C (fr)
CL (1) CL2015000169A1 (fr)
DK (1) DK2877183T3 (fr)
EA (1) EA028263B1 (fr)
ES (1) ES2848215T3 (fr)
HK (1) HK1204983A1 (fr)
IL (1) IL236868B (fr)
IN (1) IN2014DN10901A (fr)
MA (1) MA37799B2 (fr)
MX (2) MX2015001064A (fr)
MY (1) MY183944A (fr)
NZ (2) NZ703168A (fr)
PH (1) PH12014502790A1 (fr)
SG (1) SG11201500228UA (fr)
TW (1) TWI693070B (fr)
UA (1) UA114517C2 (fr)
WO (1) WO2014015416A1 (fr)
ZA (1) ZA201409179B (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
EP1441707A1 (fr) * 2001-11-09 2004-08-04 Pharmacia AB Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
CN102357248A (zh) * 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性***受体调节剂联合用于防治绝经后女性的***疾病和病症
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel

Also Published As

Publication number Publication date
MX2015001064A (es) 2015-07-14
JP2017057211A (ja) 2017-03-23
KR20150033696A (ko) 2015-04-01
CA2879648C (fr) 2017-10-31
NZ703168A (en) 2016-04-29
EP2877183B1 (fr) 2020-12-16
EP2877183A1 (fr) 2015-06-03
CN104540511A (zh) 2015-04-22
BR112015001479A2 (pt) 2017-07-04
AU2013296091B2 (en) 2016-01-07
IL236868A0 (en) 2015-03-31
JP2015522625A (ja) 2015-08-06
IN2014DN10901A (fr) 2015-09-11
WO2014015416A9 (fr) 2014-07-03
KR20170095399A (ko) 2017-08-22
EP2877183A4 (fr) 2016-03-09
JP6618887B2 (ja) 2019-12-11
PH12014502790B1 (en) 2015-02-09
AU2013296091A1 (en) 2015-01-22
EA201500165A1 (ru) 2015-07-30
CN111529536A (zh) 2020-08-14
JP6893960B2 (ja) 2021-06-23
AR091907A1 (es) 2015-03-11
EA028263B1 (ru) 2017-10-31
JP2019196404A (ja) 2019-11-14
IL236868B (en) 2020-09-30
WO2014015416A1 (fr) 2014-01-30
CL2015000169A1 (es) 2015-08-07
NZ717808A (en) 2017-08-25
SG11201500228UA (en) 2015-02-27
TWI693070B (zh) 2020-05-11
KR20200008055A (ko) 2020-01-22
HK1204983A1 (en) 2015-12-11
KR20210062746A (ko) 2021-05-31
PH12014502790A1 (en) 2015-02-09
CA2972491A1 (fr) 2014-01-30
CA2879648A1 (fr) 2014-01-30
DK2877183T3 (da) 2021-03-08
TW201408305A (zh) 2014-03-01
CA2972491C (fr) 2020-12-29
US20140045806A1 (en) 2014-02-13
ES2848215T3 (es) 2021-08-05
MY183944A (en) 2021-03-17
UA114517C2 (uk) 2017-06-26
KR102258122B1 (ko) 2021-05-28
ZA201409179B (en) 2015-12-23
MA37799B2 (fr) 2021-02-26
MX2020009333A (es) 2020-10-08

Similar Documents

Publication Publication Date Title
EA201491334A1 (ru) Композиции и способы для лечения метаболических расстройств
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IN2014KN02830A (fr)
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EP2729148A4 (fr) Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201391440A1 (ru) Производные пиразолопиримидина
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
BR112015010639A2 (pt) lactobacillus rhamnosus para redução da acumulação de gordura corporal
MA37799A1 (fr) Amélioration de l'excitation sexuelle, du désir sexuel, de l'orgasme et/ou du plaisir à la suite d'une administration de prastérone (dha) intra vaginale chez des femmes ne souffrant pas de dyspareunie ou d'autres symptômes d'atrophie vulvo-vaginale ou indépendamment de ceux-ci
SI2694065T1 (en) A composition for treating a disorder of hypoactive sexual desire
EA201492238A1 (ru) Композиция мизопростола
WO2015051234A3 (fr) Antagonistes de tweak pour traiter la néphropathie lupique et l'atrophie musculaire
MX2015001695A (es) Regimenes de tratamiento.
TH1501000324A (th) การปรับปรุงให้ดีขึ้นของความตื่นตัวทางเพศ, ความต้องการทางเพศ, ความเสียวสุดยอดทางเพศ และ/หรือ ความพึงพอใจ หลังการให้พราสเตอโรน (dhea) ในช่องคลอดในผู้หญิงที่ไม่มีหรือเป็นอิสระจากอาการปวดเฉียบขณะ ร่วมเพศหรืออาการอื่นๆ ของโยนีและช่องคลอดฝ่อลีบ
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
Chernenkov et al. The experience with the use of synbiotic in patients of a pediatric hospital
IN2014KN01142A (fr)
MX2016010022A (es) Composicion farmaceutica de amfepramona y topiramato util en el tratamiento de sobrepeso y obesidad.